These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6350024)

  • 1. Biotransformation of furosemide in kidney transplant patients.
    Smith DE; Benet LZ
    Eur J Clin Pharmacol; 1983; 24(6):787-90. PubMed ID: 6350024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of furosemide in patients with acute pulmonary edema.
    Perez J; Sitar DS; Ogilvie RI
    Drug Metab Dispos; 1979; 7(6):383-7. PubMed ID: 43224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.
    Andreasen F; Christensen CK; Jakobsen FK; Mogensen CE
    Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):223-9. PubMed ID: 7336980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the fate of furosemide in man.
    Beermann B; Dalén E; Lindström B; Rosén A
    Eur J Clin Pharmacol; 1975 Oct; 9(1):51-61. PubMed ID: 1233253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Furosemide assays and disposition in healthy volunteers and renal transplant patients.
    Benet LZ; Smith DE; Lin ET; Vincenti F; Gambertoglio JG
    Fed Proc; 1983 Apr; 42(6):1695-8. PubMed ID: 6339277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The urinary excretion of frusemide and its metabolites by kidney transplant patients.
    Nakahama H; Miwa Y; Yamaji A; Orita Y; Fukuhara Y; Yanase M; Kamada T; Sonoda T; Ishibasi M; Ichikawa Y
    Eur J Clin Pharmacol; 1987; 32(3):313-5. PubMed ID: 3297734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.
    Smith DE; Lin ET; Benet LZ
    Drug Metab Dispos; 1980; 8(5):337-42. PubMed ID: 6107232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
    Ogata H; Kawatsu Y; Maruyama Y; Machida K; Haga T
    Eur J Clin Pharmacol; 1985; 28(1):53-9. PubMed ID: 3987786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans.
    Vree TB; van der Ven AJ
    J Pharm Pharmacol; 1999 Mar; 51(3):239-48. PubMed ID: 10344623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma protein binding of furosemide in kidney transplant patients.
    Smith DE; Benet LZ
    J Pharmacokinet Biopharm; 1982 Dec; 10(6):663-74. PubMed ID: 6763626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The identification of [2-(14)C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine metabolites in humans.
    Malfatti MA; Kulp KS; Knize MG; Davis C; Massengill JP; Williams S; Nowell S; MacLeod S; Dingley KH; Turteltaub KW; Lang NP; Felton JS
    Carcinogenesis; 1999 Apr; 20(4):705-13. PubMed ID: 10223203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, distribution, metabolism, and excretion of furosemide in dogs and monkeys I: analytical methodology, metabolism, and urinary excretion.
    Yakatan GJ; Maness DD; Scholler J; Novick WJ; Doluisio JT
    J Pharm Sci; 1976 Oct; 65(10):1456-60. PubMed ID: 824434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.
    Andreasen F; Mikkelsen E
    Eur J Clin Pharmacol; 1977 Aug; 12(1):15-22. PubMed ID: 902673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furosemide kinetics and dynamics after kidney transplant.
    Smith DE; Gambertoglio JG; Vincenti F; Benet LZ
    Clin Pharmacol Ther; 1981 Jul; 30(1):105-13. PubMed ID: 7016396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.
    Rakhit A; Kochak GM; Tipnis V; Hurley ME
    Clin Pharmacol Ther; 1987 May; 41(5):580-6. PubMed ID: 3032491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biliary excretion of furosemide glucuronide in rabbits.
    Sekikawa H; Yagi N; Oda K; Kenmotsu H; Takada M; Chen HF; Lin ET; Benet LZ
    Biol Pharm Bull; 1995 Mar; 18(3):447-53. PubMed ID: 7550101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
    Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
    J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a glucuronide metabolite of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats.
    Morse MA; Eklind KI; Toussaint M; Amin SG; Chung FL
    Carcinogenesis; 1990 Oct; 11(10):1819-23. PubMed ID: 2208595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of probenecid on furosemide kinetics and natriuresis in man.
    Honari J; Blair AD; Cutler RE
    Clin Pharmacol Ther; 1977 Oct; 22(4):395-401. PubMed ID: 902452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary evaluation of furosemide-probenecid interaction in humans.
    Smith DE; Gee WL; Brater DC; Lin ET; Benet LZ
    J Pharm Sci; 1980 May; 69(5):571-5. PubMed ID: 7381747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.